- Cinepazide USP/EP/BP
-
- $1.10 / 1g
-
2021-08-07
- CAS:23887-46-9
- Min. Order: 1g
- Purity: 99.9%
- Supply Ability: 100 Tons min
- Cinepazide
-
- $0.00 / 1KG
-
2020-05-12
- CAS:23887-46-9
- Min. Order: 1KG
- Purity: 99.0%
- Supply Ability: 500 MT
- Cinepazide
-
- $2.00 / 1KG
-
2019-12-23
- CAS:23887-46-9
- Min. Order: 1KG
- Purity: ≥98%
- Supply Ability: 100kg
|
| | Cinepazide Basic information |
| Product Name: | Cinepazide | | Synonyms: | CINEPAZIDE;1-(pyrrolidin-1-ylcarbonylmethyl)-4-(3,4,5-trimethoxycinnamoyl)piperazine;PIPERAZINE,1-[2-OXO-2-(1-PYRROLIDINYL)ETHYL]-4-[1-OXO-3-(3,4,5-TRIMETHOXYPHENYL)-2-PROPENYL];1-(1-Pyrrolidinylcarbonylmethyl)-4-[3-(3,4,5-trimethoxyphenyl)acryloyl]piperazine;1-[(1-Pyrrolidinylcarbonyl)methyl]-4-[1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propenyl]piperazine;2-Propen-1-one, 1-[4-[2-oxo-2-(1-pyrrolidinyl)ethyl]-1-piperazinyl]-3-(3,4,5-trimethoxyphenyl)-;Cinepazide USP/EP/BP;Cinepazide free base | | CAS: | 23887-46-9 | | MF: | C22H31N3O5 | | MW: | 417.5 | | EINECS: | 245-928-9 | | Product Categories: | | | Mol File: | 23887-46-9.mol |  |
| | Cinepazide Chemical Properties |
| Boiling point | 637.8±55.0 °C(Predicted) | | density | 1.200±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | pka | 5.22±0.10(Predicted) | | CAS DataBase Reference | 23887-46-9(CAS DataBase Reference) |
| | Cinepazide Usage And Synthesis |
| Uses | Cinepazide is an injection in the treatment of acute myocardial infarction and its effect on serum inflammatory factors. | | Definition | ChEBI: Cinepazide is an olefinic compound. It is functionally related to a cinnamic acid. | | World Health Organization (WHO) | Cinepazide, a vasodilating agent, was first introduced into
medicine in 1974. It is used in the treatment of peripheral and cerebral vascular
disorders. Following reports of blood dyscrasias, including agranulocytosis and
thrombocytopenia, associated with the use of the drug, the Spanish Committee on
Drug Surveillance has recommended its withdrawal. In other countries, the
approved product information of preparations containing cinepazide has been
amended to include a relevant warning on these adverse effects. |
| | Cinepazide Preparation Products And Raw materials |
|